BMS
CHMP Recommends BMS' Opdivo Plus Chemo for First-Line PD-L1-Positive Gastric Cancers
The recommendation is for a narrower indication than is allowed in the US, where the FDA approved the regimen for patients regardless of PD-L1 status.
Bolt Biotherapeutics, BMS to Investigate BDC-1001, Opdivo Combination in HER2-Expressing Tumors
The portion of the ongoing Phase I/II trial investigating the combination regimen in patients with HER2-positive and -low solid tumors will begin later in 2021.
Bristol Myers CAR T-Cell Therapy Abecma Approved for Multiple Myeloma in Europe
The company is also seeking to expand its manufacturing capabilities for Abecma with plans to add a facility in the EU.
Bristol Myers Squibb Q2 Revenues Grow 16 Percent
The firm's checkpoint inhibitor Opdivo returned to growth in the quarter with sales of $1.91 billion, an increase of 16 percent compared to Q2 2020.
BridgeBio, BMS Partner to Study SHP2 Inhibitor Plus Opdivo in KRAS-Mutated Tumors
The two companies will begin a Phase I/II trial of the combination treatment in KRAS-mutated solid tumors and non-small cell lung cancer.
Mar 30, 2021